• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CYTARABINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CYTARABINE chembl:CHEMBL803 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    ARABINOSYL CYTOSINE
    U-19920
    DEPOCYTE
    DEPOCYT
    TARABINE PFS
    ARA-CYTIDINE
    NSC-287459
    CYTARABINE
    ALEXAN 100
    CYTOSAR-U
    ALEXAN
    CYTOSAR
    CYTOSINE-BETA-D-ARABINOFURANOSIDE
    CITARABINA
    CYTOSINE ARABINOSIDE
    CYTOSAR®
    CYTARABINUM
    1-BETA-D-ARABINOFURANOSYLCYTOSINE
    CYTOSINE-1-BETA-D-ARABINOFURANOSIDE
    4-AMINO-1-BETA-D-ARABINOFURANOSYL-2(1H)-PYRIMIDINONE
    CYTOSINE-Β-D-ARABINOFURANOSIDE
    DEPOCYTE®
    chemidplus:147-94-4
    pubchem.compound:6253
    rxcui:3041
    drugbank:00987
    chembl:CHEMBL803

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Drug Class antineoplastic agents
    Year of Approval 1969
    (7 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Cao X et al., 2013, RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients., Pharmacogenomics
    Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
    Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
    Stone et al., 2017, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation., N. Engl. J. Med.
    Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.
    Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia
    Galmarini et al., 2002, Potential mechanisms of resistance to cytarabine in AML patients., Leuk. Res.
    Serdjebi C et al., 2014, Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?, Pharmacogenet Genomics
    Carpi FM et al., 2013, CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population., Pharmacogenomics
    Baker JA et al., 2013, Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase., Drug Metab Dispos
    Ciccolini J et al., 2012, CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations., Pharmacogenomics
    Abraham A et al., 2012, Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia., Pharmacogenomics
    Parmar S et al., 2011, Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells., Pharmacogenomics
    Caronia D et al., 2011, A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome., Clin Cancer Res
    Mahlknecht U et al., 2009, SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival., Leukemia
    Ribelles N et al., 2008, A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression., Curr Drug Metab
    Cheong HS et al., 2014, NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia., Pharmacogenet Genomics
    Gehrmann et al., 2002, Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels., Biol. Chem.
    He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
    Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
    Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
    Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
    Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
    Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
    Caldwell et al., 2013, Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia., PLoS ONE
    Krynetskaia et al., 2009, Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage., Mol. Cancer Ther.
    Angeli et al., 2006, Anti-clastogenic effect of beta-glucan extracted from barley towards chemically induced DNA damage in rodent cells., Hum Exp Toxicol
    Miura et al., 2004, DNA polymerases as targets of anticancer nucleosides., Curr Drug Targets
    Ustun et al., 2009, Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V., Leuk. Res.
    Adams et al., 1985, Altered mouse bone marrow glutathione and glutathione transferase levels in response to cytotoxins., Cancer Res.
    Drenberg CD et al., 2016, ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression., Clin Transl Sci
    López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
    Shi JY et al., 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients., Pharmacogenetics
    Gaidzik et al., 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group., J. Clin. Oncol.
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol
  • CYTARABINE   CDA

    Interaction Score: 2.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12008078 25003625 23651026 23230131 22379997 22304580 21521023 21325291 19458626 18473752


    Sources:
    NCI PharmGKB

  • CYTARABINE   MED12L

    Interaction Score: 2.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • CYTARABINE   GATA1

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type megakaryocytic leukemia
    Response Type decreased response
    Approval Status Preclinical - Cell culture

    PMIDs:
    23874683


    Sources:
    JAX-CKB

  • CYTARABINE   SULT2B1

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • CYTARABINE   NT5C3A

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25000516


    Sources:
    PharmGKB

  • CYTARABINE   IKZF1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30044693


    Sources:
    CIViC

  • CYTARABINE   DROSHA

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24614921


    Sources:
    PharmGKB

  • CYTARABINE   SLC22A12

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • CYTARABINE   WT1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18591546


    Sources:
    CIViC

  • CYTARABINE   RRM2B

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24024897


    Sources:
    PharmGKB

  • CYTARABINE   NT5C2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CYTARABINE   BMP7

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • CYTARABINE   POLD1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CYTARABINE   LINC00251

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • CYTARABINE   POLE

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CYTARABINE   DOK5

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • CYTARABINE   DCK

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15564883


    Sources:
    PharmGKB

  • CYTARABINE   RRM2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24024897


    Sources:
    PharmGKB

  • CYTARABINE   GATA3

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • CYTARABINE   P2RY12

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • CYTARABINE   POLA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CYTARABINE   RRM1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24024897


    Sources:
    PharmGKB

  • CYTARABINE   NCOA3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYTARABINE   CYP2E1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22584460


    Sources:
    PharmGKB

  • CYTARABINE   TYMSOS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CYTARABINE   ABCC4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26842729


    Sources:
    PharmGKB

  • CYTARABINE   HSPA4

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12530536


    Sources:
    NCI

  • CYTARABINE   FLT3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cytarabine + Daunorubicin + Midostaurin
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive

    PMIDs:
    27626069 28644114 25818407 22627678


    Sources:
    JAX-CKB

  • CYTARABINE   SLCO1B1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26663398 22584460


    Sources:
    PharmGKB

  • CYTARABINE   RUNX1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21343560


    Sources:
    CIViC

  • CYTARABINE   GSTP1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3978635


    Sources:
    NCI

  • CYTARABINE   KMT2A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute lymphocytic leukemia
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27443263


    Sources:
    JAX-CKB

  • CYTARABINE   KIT

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dasatinib + Cytarabine
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive

    PMIDs:
    18986703


    Sources:
    JAX-CKB

  • CYTARABINE   POLB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CPX-351, cytarabine + daunorubicin
    Novel drug target Established target
    Trial Name cytarabine liposome injection,DepoCyt

    PMIDs:
    19372559 16866189 15011952


    Sources:
    TdgClinicalTrial TEND

  • CYTARABINE   TYMS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CYTARABINE   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25567217 25558979 20938465 16331627


    Sources:
    PharmGKB

  • CYTARABINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYTARABINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYTARABINE   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYTARABINE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYTARABINE   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CYTARABINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYTARABINE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CYTARABINE

    • Version: 01-August-2011

    Alternate Names:
    CYTARABINE Primary Drug Name

    Drug Info:
    Year of Approval 1969
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: CYTARABINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: CYTARABINE

    • Version: 14-September-2017

    Alternate Names:
    C408 NCI drug code

    Drug Info:

    Publications:
    Galmarini et al., 2002, Potential mechanisms of resistance to cytarabine in AML patients., Leuk. Res.
    Gehrmann et al., 2002, Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels., Biol. Chem.

  • NCI: 1-BETA-D-ARABINOFURANOSYLCYTOSINE

    • Version: 14-September-2017

    Alternate Names:
    C408 NCI drug code

    Drug Info:

    Publications:
    Adams et al., 1985, Altered mouse bone marrow glutathione and glutathione transferase levels in response to cytotoxins., Cancer Res.

  • DTC: CYTARABINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL803 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: cytarabine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
    Drenberg CD et al., 2016, ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression., Clin Transl Sci
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

  • JAX-CKB: Cytarabine

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Caldwell et al., 2013, Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia., PLoS ONE
    Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia
    Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.

  • CIViC: CYTARABINE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.
    Gaidzik et al., 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group., J. Clin. Oncol.
    Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

  • TTD: Cytarabine

    • Version: 2020.06.01

    Alternate Names:
    D07XSN TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL803

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL803

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21